Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk

Drug Metabolism and Disposition

Volumn 40, Issue 5, 2012, Pages 1018-1023

  Wang, Lipeng ^a   McNamara, Patrick J ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; PANTOPRAZOLE;

ADULT ANIMAL; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MILK LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ACRIDINES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; MASS SPECTROMETRY; MILK; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; TETRAHYDROISOQUINOLINES;

RATTUS;

EID: 84859921105     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041608     Document Type: Article

References (33)

1. Alcorn J and McNamara PJ (2002) Acyclovir, ganciclovir, and zidovudine transfer into rat milk. Antimicrob Agents Chemother 46:1831-1836. (Pubitemid 34535204)
2. Alcorn J, Lu X, Moscow JA, and McNamara PJ (2002) Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcriptionpolymerase chain reaction. J Pharmacol Exp Ther 303:487-496. (Pubitemid 35231217)
3. Andersson T and Weidolf L (2008) Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 28:263-279. (Pubitemid 351521381)
4. Bharathi DV, Hotha KK, Jagadeesh B, Chatki PK, Thriveni K, Mullangi R, and Naidu A (2009) Simultaneous estimation of four proton pump inhibitors-lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. Biomed Chromatogr 23:732-739.
5. Bhatia P, Kolinski M, Moaddel R, Jozwiak K, and Wainer IW (2008) Determination and modelling of stereoselective interactions of ligands with drug transporters: a key dimension in the understanding of drug disposition. Xenobiotica 38:656-675.
6. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582. (Pubitemid 40490054)
7. Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, and Schellens JH (2004) Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64:5804-5811. (Pubitemid 39095580)
8. Choong E, Dobrinas M, Carrupt PA, and Eap CB (2010) The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution. Expert Opin Drug Metab Toxicol 6:953-965.
9. Fleishaker JC and McNamara PJ (1988) In vivo evaluation in the lactating rabbit of a model for xenobiotic distribution into breast milk. J Pharmacol Exp Ther 244:919-924. (Pubitemid 18090106)
10. Fleishaker JC, Desai N, and McNamara PJ (1987) Factors affecting the milk-to-plasma drug concentration ratio in lactating women: physical interactions with protein and fat. J Pharm Sci 76:189-193. (Pubitemid 17054708)
11. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
12. He Y, Liu Y, and Zeng S (2010) Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction. Chirality 22:684-692.
13. Huang SM and Woodcock J (2010) Transporters in drug development: advancing on the Critical Path. Nat Rev Drug Discov 9:175-176.
14. Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, and Zech K (1996) Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 34:185-194. (Pubitemid 26148501)
15. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, and Schinkel AH (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129. (Pubitemid 40321346)
16. Kalvass JC and Pollack GM (2007) Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24:265-276. (Pubitemid 46072186)
17. Karlsson L, Schmitt U, Josefsson M, Carlsson B, Ahlner J, Bengtsson F, Kugelberg FC, and Hiemke C (2010) Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 20:632-640.
18. Katsuki H, Hamada A, Nakamura C, Arimori K, and Nakano M (2001) Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 57:709-715. (Pubitemid 34031263)
19. Kim J, Riggs KW, Misri S, Kent N, Oberlander TF, Grunau RE, Fitzgerald C, and Rurak DW (2006) Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol 61:155-163. (Pubitemid 43382609)
20. Mao Q and Unadkat JD (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118-E133. (Pubitemid 41554295)
21. Masubuchi N, Yamazaki H, and Tanaka M (1998) Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats. Chirality 10:747-753. (Pubitemid 28498734)
22. McDonagh MS, Carson S, and Thakurta S (2009), in Drug Class Review: Proton Pump Inhibitors: Final Report Update 5, Portland.
23. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, and Prieto JG (2006) Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
24. Miura M and Uno T (2010) Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol 6:69-74.
25. Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, and Schellens JH (2009) The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31-40.
26. Perez M, Blazquez AG, Real R, Mendoza G, Prieto JG, Merino G, and Alvarez AI (2009) In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. Chem Biol Interact 180:106-112.
27. Plante L, Ferron GM, Unruh M, and Mayer PR (2004) Excretion of pantoprazole in human breast. J Reprod Med 49:825-827.
28. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, and Ishizaki T (2001) Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther 69:108-113. (Pubitemid 32225410)
29. Tateishi T, Miura M, Suzuki T, and Uno T (2008) The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 65:693-700. (Pubitemid 351535095)
30. van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, and Schinkel AH (2006) Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27:123-130. (Pubitemid 43025252)
31. Wang L, Leggas M, Empey PE, and McNamara PJ (2012) Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis. Drug Metab Dispos 40:1024-1031.
32. Wang L, Leggas M, Goswami M, Empey PE, and McNamara PJ (2008) N-(4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9, 10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk. Drug Metab Dispos 36:2591-2596.
33. Xie Z, Zhang Y, Xu H, and Zhong D (2005) Pharmacokinetic differences between pantoprazole enantiomers in rats. Pharm Res 22:1678-1684. (Pubitemid 41355907)